MARKSANS329.00

Marksans Pharma Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,909 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,177.4262.32,950.93,171.7
Other Income50.47.082.5102.3
Total Income2,227.8269.33,033.53,274.0
Expenses
+ Cost of Materials Consumed667.775.3959.2987.2
+ Purchases of Stock-in-Trade444.357.4454.5421.4
+ Changes in Inventories-73.9-18.4-136.4-49.6
+ Employee Benefit Expense293.635.0420.9436.8
+ Finance Costs11.21.224.125.1
+ Depreciation & Amortisation74.38.398.6100.4
+ Other Expenses387.160.0651.9662.3
Total Expenses1,804.3218.92,472.92,583.5
EBITDA458.652.9600.8713.7
EBIT384.344.5502.1613.3
Profit
PBT before Exceptional Items423.550.4560.6690.5
Pretax Income423.550.4560.6690.5
+ Current Tax113.312.9153.0185.3
+ Deferred Tax-4.7-0.7-12.5-16.0
Tax Expense108.612.1140.5169.3
Net Income314.938.3420.1521.3
+ Net Income — Continuing Ops314.938.3420.1521.3
+ Other Comprehensive Income28.64.8176.1126.6
Total Comprehensive Income343.543.1596.2647.9
Net Income to Common342.60.0417.9516.7
Minority Interest0.90.02.24.5
Per Share
Basic EPS6.928.409.2211.41
Diluted EPS6.928.409.2211.41
Other Comprehensive Income — detail
+ Other Comprehensive Income4.8176.1126.6
+ Items NOT to be Reclassified to P&L0.4-0.01.41.8
+ Tax on Items NOT to be Reclassified-0.00.40.5
+ Tax on Items NOT to be Reclassified — alt tag0.1
+ Items to be Reclassified to P&L28.34.8175.1125.3
Comprehensive Income — Owners of Parent342.60.0589.2639.4
Comprehensive Income — Non-controlling Interests0.90.07.18.5
Per Share — as-filed variants
Basic EPS — Continuing Operations6.928.409.2211.41
Diluted EPS — Continuing Operations6.928.409.2211.41
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,139.3147.91,673.71,812.8
Gross Margin %52.3256.3956.7257.16
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)423.550.4560.6690.5
Net Income Adj (tax-effected)314.938.3420.1521.3
EPS Adj6.928.409.2211.41
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital45.34.545.345.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.